Ascentawits Pharma announced the interim analysis results of the AST-3424 Phase II clinical efficacy and safety study in advanced HCC at the 2024 CSCO conference

AST-3424 study presented on September 27, won the "Outstanding Paper Award"
OBI Pharma’s partner, Ascentawits Pharma Ltd., presented the interim results of the Phase II clinical efficacy and safety analysis of its new anti-cancer drug AST-3424 (also referred to as OBI-3424*) at the 2024 annual meeting of the Chinese Society of Clinical Oncology (CSCO) on September 27. The research was also awarded the "Outstanding Paper Award" by the conference.